The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study

Abstract Introduction The advances in immune checkpoint inhibitors (ICIs) were relatively slow in rare tumors. Therefore, we conducted a multi‐center study evaluating the efficacy of ICI monotherapy and the combination of ICIs with chemotherapy (CT) in patients with advanced rare tumors. Methods In...

Description complète

Détails bibliographiques

Auteurs principaux:	Deniz Can Guven, Musa Baris Aykan, Harun Muglu, Ertugrul Bayram, Kaan Helvaci, Bengü Dursun, Melisa Celayir, Elvin Chelebiyev, Erdinc Nayir, Mustafa Erman, Ahmet Sezer, Yuksel Urun, Umut Demirci, Ozlem Er, Umut Disel, Ahmet Bilici, Cagatay Arslan, Nuri Karadurmus, Saadettin Kilickap
Format:	Artigo
Langue:	Inglês
Publié:	Wiley 2024-01-01
Collection:	Cancer Medicine
Sujets:	immune checkpoint inhibitor immunotherapy rare tumor sarcoma
Accès en ligne:	https://doi.org/10.1002/cam4.6869
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!